Compounds that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SlP receptors.
sulfonamides with carboxylic acid anhydrides in the presence of Lewisacids is described. Several Lewisacids such as BF3·Et2O, ZnCl2, MoCl5, TiCl4, B(C6F5)3, Sc(OTf)3 and I2 were found to catalyze the reactionefficiently to furnish the N-acylated products in good yields undersolvent-freeconditions. The reactions of various sulfonamides were studied with different carboxylic acid anhydrides including the
Facile Synthesis of<i>N</i>‐Acylsulfonamide in the Presence of Silica Chloride (SiO<sub>2</sub>‐Cl) both under Heterogeneous and Solvent‐Free Conditions
Abstract Sulfonamides were converted to the corresponding N‐acyl sulfonamides with carboxylic acid chlorides and anhydrides in the presence of silica chloride. All reactions were performed in bothheterogeneous and solvent‐freeconditions. This method provides the N‐acyl sulfonamides products in good to high yield and purity.
Synthesis, in vitro antibacterial and carbonic anhydrase II inhibitory activities of N-acylsulfonamides using silica sulfuric acid as an efficient catalyst under both solvent-free and heterogeneous conditions
Silicasulfuricacid catalyzes efficiently the reaction of sulfonamides with both carboxylic acid anhydrides and chlorides undersolvent-free and heterogeneous conditions. All the reactions were done at room temperature and the N-acylsulfonamides were obtained with high yields and purity via an easy work-up procedure. This method is attractive and is in a close agreement with green chemistry. These
[EN] SUBSTITUTED INDOLE MCL-1 INHIBITORS<br/>[FR] INHIBITEURS DE MCL-1 DE TYPE INDOLE SUBSTITUÉ
申请人:UNIV VANDERBILT
公开号:WO2015031608A1
公开(公告)日:2015-03-05
The present application, among other things, provides compounds that are capable of inhibiting the activity of anti-apoptotic Bcl-2 family proteins, for example, myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides pharmaceutical compositions as well as methods for using provided compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein. In some embodiments, a provided compound has the structure of formula I. In some embodiments, a provided compound has the structure of formula II.